Clean Harbors, Inc. (CLH) Forms $52.40 Double Bottom; Pacira Pharmaceuticals (PCRX)’s Sentiment Is 1.39

February 19, 2018 - By Lawrence Diaz

Clean Harbors, Inc. (CLH) formed double bottom with $50.83 target or 3.00% below today’s $52.40 share price. Clean Harbors, Inc. (CLH) has $2.98 billion valuation. The stock increased 1.89% or $0.97 during the last trading session, reaching $52.4. About 173,196 shares traded. Clean Harbors, Inc. (NYSE:CLH) has risen 18.53% since February 19, 2017 and is uptrending. It has outperformed by 1.83% the S&P500.

Pacira Pharmaceuticals, Inc., a specialty pharmaceutical company, develops, makes, and commercializes proprietary pharmaceutical products primarily for use in hospitals and ambulatory surgery centers in the United States. The company has market cap of $1.22 billion. It develops pharmaceutical products based on its proprietary DepoFoam drug delivery technology. It currently has negative earnings. The companyÂ’s lead product includes, EXPAREL, a liposome injection of bupivacaine, an amide-type local anesthetic indicated for infiltration into the surgical site to produce postsurgical analgesia.

Analysts await Clean Harbors, Inc. (NYSE:CLH) to report earnings on February, 28. They expect $0.06 earnings per share, up 200.00% or $0.12 from last year’s $-0.06 per share. CLH’s profit will be $3.42M for 218.33 P/E if the $0.06 EPS becomes a reality. After $0.21 actual earnings per share reported by Clean Harbors, Inc. for the previous quarter, Wall Street now forecasts -71.43% negative EPS growth.

Among 14 analysts covering Clean Harbors Inc. (NYSE:CLH), 6 have Buy rating, 0 Sell and 8 Hold. Therefore 43% are positive. Clean Harbors Inc. had 39 analyst reports since July 27, 2015 according to SRatingsIntel. As per Wednesday, April 12, the company rating was maintained by Wedbush. The company was downgraded on Tuesday, January 10 by Barclays Capital. On Thursday, November 3 the stock rating was maintained by Needham with “Buy”. The firm has “Buy” rating given on Wednesday, January 10 by BMO Capital Markets. Stifel Nicolaus maintained the stock with “Buy” rating in Monday, August 28 report. Raymond James downgraded the shares of CLH in report on Monday, July 27 to “Market Perform” rating. The firm has “Neutral” rating by Macquarie Research given on Friday, August 26. Goldman Sachs initiated Clean Harbors, Inc. (NYSE:CLH) rating on Friday, March 3. Goldman Sachs has “Neutral” rating and $60 target. On Monday, August 7 the stock rating was upgraded by Barclays Capital to “Hold”. The rating was initiated by Barclays Capital with “Overweight” on Wednesday, May 18.

Since August 24, 2017, it had 0 buys, and 3 selling transactions for $313,845 activity. On Friday, September 8 Dugas Eric J. sold $51,007 worth of Clean Harbors, Inc. (NYSE:CLH) or 933 shares. Shares for $27,528 were sold by Weber Brian P on Friday, September 29. GERSTENBERG ERIC W had sold 4,667 shares worth $235,310.

Investors sentiment decreased to 1.01 in Q3 2017. Its down 0.21, from 1.22 in 2017Q2. It is negative, as 18 investors sold Clean Harbors, Inc. shares while 75 reduced holdings. 32 funds opened positions while 62 raised stakes. 52.13 million shares or 1.97% less from 53.18 million shares in 2017Q2 were reported. Bernzott Capital Advsr stated it has 219,287 shares. Aperio Lc holds 12,716 shares or 0% of its portfolio. Winfield Incorporated invested 0% in Clean Harbors, Inc. (NYSE:CLH). Bnp Paribas Arbitrage owns 18,169 shares. Timessquare Limited holds 0.36% or 954,060 shares in its portfolio. Canada Pension Plan Invest Board accumulated 1,100 shares. Hbk Invs Lp accumulated 17,000 shares. State Board Of Administration Of Florida Retirement, a Florida-based fund reported 77,288 shares. Intrust Retail Bank Na reported 0.09% in Clean Harbors, Inc. (NYSE:CLH). Parametric Assoc Limited Com owns 147,962 shares for 0.01% of their portfolio. Cwm Ltd Liability holds 0.1% or 38,292 shares in its portfolio. Thompson Siegel Walmsley Ltd Liability owns 0% invested in Clean Harbors, Inc. (NYSE:CLH) for 14 shares. Intll Gru Inc owns 106,402 shares for 0.02% of their portfolio. Royal Bancshares Of Canada reported 790,640 shares or 0.02% of all its holdings. Sfe Counsel holds 25,555 shares.

Analysts await Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) to report earnings on March, 7. They expect $-0.08 earnings per share, up 33.33% or $0.04 from last year’s $-0.12 per share. After $-0.11 actual earnings per share reported by Pacira Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts -27.27% EPS growth.

Consonance Capital Management Lp holds 5.73% of its portfolio in Pacira Pharmaceuticals, Inc. for 1.38 million shares. Venbio Select Advisor Llc owns 1.31 million shares or 3.82% of their US portfolio. Moreover, Healthcor Management L.P. has 3.24% invested in the company for 2.58 million shares. The New York-based 40 North Management Llc has invested 3.16% in the stock. Daruma Capital Management Llc, a New York-based fund reported 1.22 million shares.

Ratings analysis reveals 71% of Pacira Pharma’s analysts are positive. Out of 7 Wall Street analysts rating Pacira Pharma, 5 give it “Buy”, 0 “Sell” rating, while 2 recommend “Hold”. The lowest target is $34.0 while the high is $93.0. The stock’s average target of $54.83 is 81.86% above today’s ($30.15) share price. PCRX was included in 7 notes of analysts from October 19, 2016. The stock of Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) earned “Outperform” rating by Wedbush on Wednesday, October 19. Goldman Sachs initiated Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) on Thursday, December 1 with “Neutral” rating. Canaccord Genuity initiated the stock with “Buy” rating in Wednesday, February 22 report. The firm has “Buy” rating by Mizuho given on Thursday, November 3. Janney Capital maintained it with “Neutral” rating and $34.0 target in Friday, December 30 report. H.C. Wainwright initiated Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) rating on Tuesday, January 3. H.C. Wainwright has “Buy” rating and $43.0 target. On Thursday, April 13 the stock rating was initiated by RBC Capital Markets with “Outperform”.

The stock decreased 16.48% or $5.95 during the last trading session, reaching $30.15. About 3.92M shares traded or 342.64% up from the average. Pacira Pharmaceuticals, Inc. (PCRX) has risen 12.40% since February 19, 2017 and is uptrending. It has underperformed by 4.30% the S&P500.

Since January 1, 0001, it had 0 insider buys, and 2 insider sales for $1.18 million activity.

- Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


>